secwatch.observer — SEC 8-K summary
======================================

Issuer:     Voyager Therapeutics, Inc. (VYGR)
CIK:        0001640266
Form:       8-K
Filed at:   2022-02-03T23:59:59+00:00
Accession:  0001104659-22-011398
Event type: leadership
Sentiment:  positive
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Voyager Therapeutics appoints ex-Biogen EVP Alfred Sandrock to board, names Robin Swartz COO
--------------------------------------------------------------------------------

- Alfred Sandrock, former Biogen EVP R&D, appointed to Board effective Feb 7, 2022; consulting agreement at $30k/month.
- Robin Swartz promoted to COO; base salary $420k, target bonus 40%, and option grant of 65,000 shares.
- Sandrock receives standard director compensation: $40k annual cash, initial option for 44,000 shares, plus committee fees.
- Swartz's employment extends COBRA premium payments to 12 months on qualifying termination.
- Both appointments effective Feb 7, 2022; Sandrock's term runs until 2023 annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1640266/000110465922011398/0001104659-22-011398-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1640266/000110465922011398/tm225066d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-011398

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer